ArticleCancers2020
MAT2A as Key Regulator and Therapeutic Target in
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Silencing of MAT2A inhibits gastric cancer cell proliferation, migration, and invasion through activation of the p53 pathway.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Methionine restriction in cancer: a dietary insight for therapy.Frontiers in nutrition · 2026Review
- A novel role of secreted methionine adenosyltransferase α2 in colorectal liver metastases.Journal of experimental & clinical cancer research : CR · 2025Article
- Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential.Pharmaceuticals (Basel, Switzerland) · 2025Review
- PRPS2 enhances RNA mNature communications · 2025Article
- Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma.Cell reports. Medicine · 2025Article
- Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets.Cell reports. Medicine · 2025Article
- Only InfantInternational journal of molecular sciences · 2024Article
- NMolecular medicine (Cambridge, Mass.) · 2024Review
- SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with theMedComm · 2024Article
- 8-Cl-Ado and 8-NHLeukemia · 2024Article
- The RORɣ/SREBP2 pathway is a master regulator of cholesterol metabolism and serves as potential therapeutic target in t(4;11) leukemia.Oncogene · 2024Article
- MAT2A inhibition suppresses inflammation inJournal of oral microbiology · 2024Article
- Bidirectional interplay between metabolism and epigenetics in hematopoietic stem cells and leukemia.The EMBO journal · 2023Review
- Uncovering NOTCH1 as a Promising Target in the Treatment ofInternational journal of molecular sciences · 2023Article
- A Leukemic Target with a Thousand Faces: The Mitochondria.International journal of molecular sciences · 2023Review
- Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.Neoplasia (New York, N.Y.) · 2023Article
- Interplay between the EMT transcription factors ZEB1 and ZEB2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity.PLoS biology · 2021Article
- Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Epigenetic dysregulation plays a pivotal role in mixed-lineage leukemia (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.